Search - tctmd.com

Displaying 561 - 580 of 762

Sort: Relevancy | Date

News Daily News

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Michael O'Riordan

December 09, 2016

News Daily News

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Michael O'Riordan

December 09, 2016

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

News Daily News

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

Michael O'Riordan

December 01, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

脂质损失：国家数据显示总胆固醇、甘油三酯和低密度脂蛋白大大降低

Yael L. Maxwell

November 30, 2016

News Daily News

Lipid Losses: National Data Show Drastic Drops in Total Cholesterol, Triglycerides, and LDL

Yael L. Maxwell

November 30, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Conference News AHA 2016

Declines in Cognition and Function Unaffected by Lowering BP, LDL Cholesterol in the Elderly: HOPE-3

Todd Neale

November 13, 2016

News Daily News

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

Michael O'Riordan

November 13, 2016

News Daily News

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

Michael O'Riordan

November 10, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

News Daily News

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Michael O'Riordan

November 01, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

Advertisement

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

PCSK9的变体与低LDL胆固醇和糖尿病风险增加相关

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

脂质损失：国家数据显示总胆固醇、甘油三酯和低密度脂蛋白大大降低

Lipid Losses: National Data Show Drastic Drops in Total Cholesterol, Triglycerides, and LDL

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Declines in Cognition and Function Unaffected by Lowering BP, LDL Cholesterol in the Elderly: HOPE-3

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

FH Screening Started at Time of Childhood Immunization Feasible and Effective

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content